Association of Valproic Acid and Incident Breast Cancer in a Managed Care Cohort

摘要

The possible role of histone deacetylase inhibitors (HDACi) in breast cancer treatment is an area of active investigation. However, its potential as a preventive agent has not been studied. Valproic acid (VPA) is an HDACi which has been used for many decades to safely treat neurological disorders. The rationale for the use of HDACi in breast cancer prevention is a previously unexplored area of research that is based on compelling preclinical data.